Loading the security overview…
Where the tokens are
First the companies classified under the same themes, most themes in common first; then the ones investors most often look at alongside RXRX. A peer with a tokenized version links to its own page, where every issuer that wraps it is listed.
| Company | Shared themes | Market cap | P/E | P/S | EV/EBITDA | ROE | F-Score | Altman zone |
|---|---|---|---|---|---|---|---|---|
| — | $2.18B | — | 39.8 | -3.5 | −56.7% | 4/9 | distress | |
| AI-Powered Analytics & Decision SystemsClinical-Stage Platforms | $2.28B | — | 8.8 | -13.5 | −16.5% | 3/9 | safe | |
| AI-Powered Analytics & Decision SystemsClinical-Stage Platforms | $1.42B | — | 3.5 | 22.1 | −7.1% | 6/9 | safe | |
| AI-Powered Analytics & Decision SystemsClinical-Stage Platforms | $960.63M | — | 33.4 | -5.0 | −33.1% | 3/9 | safe | |
| AI-Powered Analytics & Decision SystemsClinical-Stage Platforms | $373.96M | 46.1 | 4.6 | 19.8 | 5.8% | 5/9 | safe | |
| AI-Powered Analytics & Decision SystemsClinical-Stage Platforms | $71.38M | — | 713.8 | -0.7 | −28.1% | 2/9 | distress | |
| AI-Powered Analytics & Decision Systems | $456.68B | 151.4 | 74.2 | 170.8 | 30.9% | 7/9 | safe | |
| AI-Powered Analytics & Decision Systems | $272.46B | 4660.6 | 50.5 | 1258.2 | 1.1% | 3/9 | safe | |
| Clinical-Stage Platforms | $241.26B | 34.6 | 5.2 | 24.6 | 13.2% | 6/9 | safe | |
| AI-Powered Analytics & Decision Systems | $120.65B | — | 22.2 | -123.2 | −50.7% | 4/9 | safe | |
| AI-Powered Analytics & Decision Systems | $99.27B | 559.0 | 25.0 | 655.9 | 4.1% | 6/9 | safe | |
| AI-Powered Analytics & Decision Systems | $94.14B | 21.4 | 13.8 | 17.4 | 139.4% | 8/9 | safe | |
| AI-Powered Analytics & Decision Systems | $63.82B | — | — | — | — | 7/9 | — | |
| Clinical-Stage Platforms | $46.99B | 32.6 | 6.4 | 25.8 | 19.6% | 6/9 | safe | |
| Clinical-Stage Platforms | $42.91B | 31.2 | 2.5 | 16.1 | 22.3% | 5/9 | grey |
Figures describe Recursion Pharmaceuticals shares, not any token. From theme classifications, Massive's related companies and the latest ratios and scores. Ratios are trailing, each as of its own latest filing. Peers are for comparison, not a list of alternatives to buy.